Smith & Nephew PLC - Asset Resilience Ratio
Smith & Nephew PLC (SN) has an Asset Resilience Ratio of -0.69% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1985–2023)
This chart shows how Smith & Nephew PLC's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Smith & Nephew PLC to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Smith & Nephew PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SN stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX-69.00 Million | -0.69% |
| Total Liquid Assets | GBX-69.00 Million | -0.69% |
Asset Resilience Insights
- Limited Liquidity: Smith & Nephew PLC maintains only -0.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Smith & Nephew PLC Industry Peers by Asset Resilience Ratio
Compare Smith & Nephew PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Edwards Lifesciences Corp
NYSE:EW |
Medical Devices | 9.20% |
|
DexCom Inc
NASDAQ:DXCM |
Medical Devices | 19.55% |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033 |
Medical Devices | 19.31% |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212 |
Medical Devices | 6.09% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Corentec Co Ltd
KQ:104540 |
Medical Devices | 2.80% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
Annual Asset Resilience Ratio for Smith & Nephew PLC (1985–2023)
The table below shows the annual Asset Resilience Ratio data for Smith & Nephew PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.69% | GBX-69.00 Million ≈ $-8.40K |
GBX9.99 Billion ≈ $1.22 Million |
+0.98pp |
| 2021-12-31 | -1.67% | GBX-182.00 Million ≈ $-22.14K |
GBX10.92 Billion ≈ $1.33 Million |
-0.46pp |
| 2020-12-31 | -1.21% | GBX-133.00 Million ≈ $-16.18K |
GBX11.01 Billion ≈ $1.34 Million |
-0.07pp |
| 2019-12-31 | -1.14% | GBX-106.00 Million ≈ $-12.90K |
GBX9.30 Billion ≈ $1.13 Million |
+0.00pp |
| 2018-12-31 | -1.14% | GBX-92.00 Million ≈ $-11.19K |
GBX8.06 Billion ≈ $980.55K |
-0.35pp |
| 2017-12-31 | -0.79% | GBX-62.00 Million ≈ $-7.54K |
GBX7.87 Billion ≈ $957.06K |
-0.80pp |
| 2015-12-31 | 0.01% | GBX1.00 Million ≈ $121.67 |
GBX7.17 Billion ≈ $872.02K |
-2.95pp |
| 2012-12-31 | 2.96% | GBX167.00 Million ≈ $20.32K |
GBX5.64 Billion ≈ $686.47K |
-0.03pp |
| 2011-12-31 | 2.99% | GBX142.00 Million ≈ $17.28K |
GBX4.75 Billion ≈ $577.57K |
+2.68pp |
| 2009-12-31 | 0.31% | GBX14.00 Million ≈ $1.70K |
GBX4.57 Billion ≈ $555.43K |
-4.16pp |
| 2005-12-31 | 4.47% | GBX133.00 Million ≈ $16.18K |
GBX2.98 Billion ≈ $362.09K |
-2.12pp |
| 2004-12-31 | 6.59% | GBX192.27 Million ≈ $23.39K |
GBX2.92 Billion ≈ $355.22K |
-8.84pp |
| 2003-12-31 | 15.43% | GBX342.86 Million ≈ $41.72K |
GBX2.22 Billion ≈ $270.44K |
+15.33pp |
| 1995-12-31 | 0.10% | GBX1.24 Million ≈ $150.41 |
GBX1.27 Billion ≈ $154.82K |
-0.13pp |
| 1994-12-31 | 0.22% | GBX2.97 Million ≈ $361.42 |
GBX1.32 Billion ≈ $160.83K |
0.00pp |
| 1993-12-31 | 0.23% | GBX2.96 Million ≈ $359.95 |
GBX1.31 Billion ≈ $159.01K |
-0.77pp |
| 1991-12-31 | 0.99% | GBX15.72 Million ≈ $1.91K |
GBX1.58 Billion ≈ $192.56K |
-6.44pp |
| 1990-12-31 | 7.43% | GBX114.00 Million ≈ $13.87K |
GBX1.53 Billion ≈ $186.61K |
-1.81pp |
| 1989-12-31 | 9.24% | GBX125.00 Million ≈ $15.21K |
GBX1.35 Billion ≈ $164.62K |
+3.48pp |
| 1988-12-31 | 5.76% | GBX73.34 Million ≈ $8.92K |
GBX1.27 Billion ≈ $154.90K |
-2.86pp |
| 1987-12-31 | 8.62% | GBX105.86 Million ≈ $12.88K |
GBX1.23 Billion ≈ $149.34K |
+2.47pp |
| 1986-12-31 | 6.16% | GBX54.70 Million ≈ $6.66K |
GBX888.50 Million ≈ $108.10K |
-2.22pp |
| 1985-12-31 | 8.37% | GBX53.88 Million ≈ $6.56K |
GBX643.40 Million ≈ $78.28K |
-- |
About Smith & Nephew PLC
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; t… Read more